Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax Meeting Abstract
| Authors: | Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; Hill, B. T.; Brander, D. M.; Shadman, M.; Ujjani, C. S.; Battiato, K. E.; Komari, C. J.; Sacchi De Carmago Correia, G; Aronson, J. H.; Rhodes, J. M.; Ghione, P.; Fakhri, B.; Barr, P. M.; Portell, C. A.; Lamanna, N.; Pinilla-Ibarz, J.; Zelenetz, A. D.; Schuster, S. J.; Allan, J. N.; Eyre, T. A.; Mato, A. R. |
| Abstract Title: | Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Series Title: | 198478 |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413902141 |
| DOI: | 10.1182/blood-2021-150751 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2628 -- Hybrid meeting, also took place online -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
